171 articles for regulatory affairs professionals in pharma, biotech and medical devices: career guidance, role profiles, hiring trends and policy explainers. Updated Oct 10, 2026.
5,000+ job seekers
joined our newsletter
Showing 1–12 of 63 articles
A practical guide to resigning from a regulatory affairs role: timing, knowledge transfer, submission handoffs, and protecting references and relationships on the way out.
How to use informational interviews to break into regulatory affairs: who to ask, what to say, what to actually learn, and how to follow up well.
What restrictive covenants in a regulatory affairs offer letter actually restrict, how to read them, and practical questions to raise before you sign.
Why regulatory affairs is especially fertile ground for imposter syndrome, and what actually helps: peer networks, reframing uncertainty, honest self-assessment.
Looking for a new regulatory affairs role while still employed takes real discipline. Here's how to search discreetly without jeopardizing your current job.
What it actually takes to be the sole regulatory affairs hire at a small company: the broader scope, the strategy ownership, and the real tradeoffs.
Regulatory CMC and clinical regulatory affairs mean different daily work and different long-term trajectories. How to think through the early-career choice.
What ICH guidelines actually are, the Q/S/E/M families regulatory affairs work runs on daily, and why harmonization still leaves room for regional expertise.
A practical look at how the regulatory affairs job itself changes moving from big pharma to a small biotech, from scope and speed to compensation and risk.
Reaching Chief Regulatory Officer takes more than tenure. Here's how the path actually unfolds, what separates candidates who reach the C-suite, and where the role differs from VP or Head of Regulatory Affairs.
A rescinded offer in regulatory affairs is rare but does happen, often around funding events. Here's how to respond, protect yourself, and move your search forward.
A complete response letter is not a rejection. Here's how regulatory affairs teams actually read it, build the response, and manage the resubmission.
